MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.17 0.86

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.13

Max

1.2

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+239.32% upside

Turustatistika
By TradingEconomics
Turukapital	-80M 414M
Eelmine avamishind	0.31
Eelmine sulgemishind	1.17

Uudiste sentiment

By Acuity

39%

61%

143 / 372 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. jaan 2026, 23:08 UTC

Omandamised, ülevõtmised, äriostud

Rio Tinto, Glencore in Talks to Form World's Biggest Miner -- 3rd Update

8. jaan 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Glencore, Rio Tinto Restart Merger Talks -- 2nd Update

8. jaan 2026, 20:54 UTC

Omandamised, ülevõtmised, äriostud

Glencore, Rio Tinto Restart Merger Talks -- Update

8. jaan 2026, 20:44 UTC

Omandamised, ülevõtmised, äriostud

Glencore, Rio Tinto Restart Merger Talks

8. jaan 2026, 17:05 UTC

Omandamised, ülevõtmised, äriostud

Chinese Anta Sports Products Offers to Buy Pinault Family's Stake in Puma, Reuters Says, Citing Unnamed Sources

8. jaan 2026, 16:43 UTC

Suurimad hinnamuutused turgudel

Babcock & Wilcox Shares Rise on Siemens Deal for Data Center Project

8. jaan 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8. jaan 2026, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Geopolitical Risks -- Market Talk

8. jaan 2026, 22:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. jaan 2026, 22:42 UTC

Market Talk

RBA Still Battling a Troubling Inflation Outlook, Says TD -- Market Talk

8. jaan 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Glencore, Rio Tinto Confirm Early Merger Talks -- Barrons.com

8. jaan 2026, 21:53 UTC

Tulu

These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. jaan 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. jaan 2026, 21:10 UTC

Omandamised, ülevõtmised, äriostud

Rio Tinto Says Current Expectation That Any Deal Would Involve Buying Glencore Via Scheme of Arrangement

8. jaan 2026, 21:09 UTC

Market Talk

Oil Rises As Trump Said to Back Russia Sanctions Bill -- Market Talk

8. jaan 2026, 21:09 UTC

Omandamised, ülevõtmised, äriostud

Rio Tinto Confirms in Talks With Glencore Over Possible Merger

8. jaan 2026, 20:21 UTC

Market Talk

U.S. Natural Gas Futures Down Despite Inventory Draw -- Market Talk

8. jaan 2026, 19:44 UTC

Market Talk

Gold's Shine Masks Deep Drops in Canada Steel, Aluminum Exports -- Market Talk

8. jaan 2026, 18:50 UTC

Market Talk

Mexico's Industrial Production Seen Lower in November -- Market Talk

8. jaan 2026, 17:48 UTC

Tulu

These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8. jaan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. jaan 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

8. jaan 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. jaan 2026, 16:45 UTC

Market Talk

Goldman Lifts 1H LME Copper Forecast -- Market Talk

8. jaan 2026, 16:03 UTC

Market Talk

Global Equities Roundup: Market Talk

8. jaan 2026, 16:03 UTC

Market Talk

Currency Markets Could Be Underpricing Medium-Term Risks -- Market Talk

8. jaan 2026, 16:02 UTC

Market Talk

U.S. Natural Gas Inventories Fall As Expected -- Market Talk

8. jaan 2026, 15:23 UTC

Omandamised, ülevõtmised, äriostud

Paramount Defends Its Hostile Bid for Warner -- Update

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

239.32% tõus

12 kuu keskmine prognoos

Keskmine 3.97 USD 239.32%

Kõrge 6 USD

Madal 1.9 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

143 / 372 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.